Chris Molloy responds to the Government’s Industrial Strategy White Paper
“The Medicines Discovery Catapult welcomes the Industrial Strategy white paper, published today. Investment in life sciences is vital for the continued economic success of the country, so it’s encouraging to see the government’s ongoing commitment to R&D with further investment”.
“The Catapults are an important and successful part of the UK’s ‘innovation ecosystem’ and play a vital role in delivering the Industrial Strategy, driving innovation and economic benefit in the UK. At the Medicines Discovery Catapult we actively support innovation and remove obstacles to progress by encouraging collaboration across the UK’s medicines R&D community. Ultimately our work will feed the medicines pipeline, driving the technology that will deliver drugs to patients faster.”
The Industrial Strategy: Building a Britain fit for the future is available here
PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.
Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.
